Expression of messenger RNA for transforming growth factor-beta1 and for transforming growth factor-beta receptors in peripheral blood of systemic lupus erythematosus patients treated with low doses of quinagolide

References

• Casali P. Polyclonal B cell activation and antigen-driven antibody response as mechanisms of autoantibody production in SLE. Autoimmunity 1990; 5: 147–150
   PubMed Web of Science ®Google Scholar
• Hrycek A, Kuśmierz D, Mazurek U, Wilczok T. Human cytomegalovirus in patients with systemic lupus erythematosus. Autoimmunity 2005; 38: 487–491
   PubMed Web of Science ®Google Scholar
• De Albuquerque DA, Ebling FM, Lienesch DW, Singh RR, Hahn BH. Analyses of serum levels of type 1, type 2 and type 3 cytokines reveal multiple abnormalities in lupus-prone (NZB × NZW) F1 mice. APLAR J Rheumatol 2004; 7: 3–10
   Google Scholar
• Morimoto S, Tokano Y, Kaneko H, Nozawa K, Amano H, Hashimoto H. The increased interleukin-13 in patients with systemic lupus erythematosus relations to other Th-1, Th-related cytokines and clinical findings. Autoimmunity 2001; 34: 19–25
   PubMed Web of Science ®Google Scholar
• Youinou P, Le Corre R. The multi-faceted role of transforming growth factor-beta in systemic lupus erythematosus. Lupus 1999; 8: 87–88
   Google Scholar
• Schotte H, Willeke P, Rust S, Assmann G, Domschke W, Gaubitz M, Schlüter B. The transforming growth factor-β1 gene polymorphism (G915C) is not associated with systemic lupus erythematosus. Lupus 2003; 12: 86–92
   PubMed Web of Science ®Google Scholar
• Hrycek A. Prolactin in immunological processes. Wiad Lek 1998; 51: 226–233
   Google Scholar
• Richards SM, Garman RD, Keyes L, Kavanagh B, McPherson JM. Prolactin is an antagonist of TGF-β activity and promotes proliferation of murine B cell hybridomas. Cell Immunol 1998; 184: 85–91
   PubMed Web of Science ®Google Scholar
• Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA. Decreased production of TGF-β by lymphocytes from patients with systemic lupus erythematosus. J Immunol 1998; 160: 2539–2545
   PubMed Web of Science ®Google Scholar
• Ohtsuka K, Gray JD, Stimmler MM, Horwitz DA. The relationship between defects in lymphocyte production of transforming growth factor-β1 in systemic lupus erythematosus and disease activity or severity. Lupus 1999; 8: 90–94
   PubMedGoogle Scholar
• Lu L-Y, Cheng H-H, Sung P-K, Shiue J, Chen A. Single-nucleotide polymorphisms of transforming growth factor-beta1 in Taiwanese patients with systemic lupus erythematosus. J Microbiol Immunol Infect 2004; 37: 145–152
   PubMedGoogle Scholar
• Robak E, Woźniacka A, Sysa-Jędrzejowska A, Stępień H, Robak T. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Eur Cytokine Netw 2001; 12: 445–452
   PubMed Web of Science ®Google Scholar
• Hrycek A, Siekiera U, Cieślik P, Szkróbka W. HLA-DRB1 and -DQB1 alleles and gene polymorphisms of selected cytokines in systemic lupus erythematosus. Rheumtol Int 2005; 26: 1–6
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, Mc Shane DJ, Rothfield NF, Schaller JG, Talal N, Winclester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277
   PubMed Web of Science ®Google Scholar
• Chomczyński P, Sacchi N. Single-step method of RNA isolation by acid guanidinium-thiocyanate phenol–chloroform extraction. Anal Biochem 1987; 162: 156–159
   PubMed Web of Science ®Google Scholar
• Woszczyk D, Gola J, Jurzak M, Mazurek U, Mykała-Cieśla J, Wilczok T. Expression of TGFβ1 genes and their receptor types I, II and III in low- and high-grade malignancy non-Hodgkin's lymphomas. Med Sci Monit 2004; 10: CR33–CR37
   Google Scholar
• Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T. Molecular structure of the human cytoplasmic beta-actin gene: Interspecies homology of sequences in the introns. Proc Natl Acad Sci USA 1985; 82: 6133–6137
   PubMed Web of Science ®Google Scholar
• Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985; 316: 701–705
   PubMed Web of Science ®Google Scholar
• Itoh S, Thorikay M, Kowanetz M, Moustakas A, Itoh F, Heldin CH, ten Dijke P. Elucidation of Smad requirement in transforming growth factor-beta type I receptor-induced responses. J Biol Chem 2003; 278: 3751–3761
   PubMed Web of Science ®Google Scholar
• Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF. Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992; 68: 775–785
   PubMed Web of Science ®Google Scholar
• Lopez-Casillas F, Cheifetez S, Doody J, Andres JL, Lane WS, Massague J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 1991; 67: 785–795
   PubMed Web of Science ®Google Scholar
• Sawicki F. Elements of statistics for doctors. Polish Scientific Publishers, Warsaw 1992
   Google Scholar
• Letterio JJ, Bottinger EP. TGF-β knockout and dominant-negative receptor transgenic mice. Miner Electrolyte Metab 1998; 24: 161–167
   PubMedGoogle Scholar
• Piccirillo CA, Chang Y, Prud'homme GJ. TGF-beta 1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J Immunol 1998; 161: 3950–3956
   PubMed Web of Science ®Google Scholar
• Chu HW, Trudeau JB, Balzar S, Wenzel SE. Peripheral blood and airway tissue expression of transforming growth factor β by neutrophils in asthmatic subjects and normal control subjects. J Allergy Clin Immunol 2000; 106: 1115–1123
   Google Scholar
• Sarkar DK, Chaturvedi K, Oomizu S, Boyadjieva NI, Chen CP. Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-β1, and TGF-β type II receptor interact to inhibit the growth of pituitary lactotropes. Endocrinology 2005; 146: 4179–4188
   Google Scholar
• Rovensky J, Lackovic V, Veselkova Z, Horvathova M, Koska J, Blazickova S, Vigas M. Plasma cytokine concentration and the cytokine producing ability of whole blood cell cultures from healthy females with pharmacologically induced hyperprolactinemia. Int J Tissue React 1999; 21: 43–49
   Google Scholar
• Correale J, Arias M, Gilmore W. Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol 1998; 161: 3365–3374
   PubMed Web of Science ®Google Scholar
• Wickert L, Abiaka M, Bolkenius U, Gressner AM. Corticisteroids stimulate selectively transforming growth factor (TGF)-β receptor type III expression in transdifferentiating hepatic stellate cells. J Hepatol 2004; 40: 69–76
   PubMed Web of Science ®Google Scholar
• Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003; 113: 685–700
   PubMed Web of Science ®Google Scholar
• Song S-L, Gong Z-J, Zhang Q-R, Huang T-X. Effects of Chinese traditional compound, JinSanE, on expression of TGF-β1 and TGF-β1 type II receptor mRNA, Smad3 and Smad7 on experimental hepatic fibrosis in vivo. World J Gastroenterol 2005; 11: 2269–2276
   PubMed Web of Science ®Google Scholar
• Yata Y, Gotwals Ph, Koteliansky V, Rockey DC. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-β soluble receptor: Implications for antifibrotic therapy. Hepatology 2002; 35: 1022–1030
   PubMed Web of Science ®Google Scholar
• Chen Ch, Wang X-F, Sun L. Expression of transforming growth factor β (TGFβ) type III receptor restores autocrine TGFβ1 activity in human breast cancer MCF-7 cells. Am Soc Biochem Mol Biol, Inc 1997; 272: 12862–12867
   Google Scholar
• Zwaagstra JC, Kassam Z, O'Connor-McCourt MD. Down-regulation of transforming growth factor-β receptors: Cooperativity between the types I, II and III receptors and modulation at the cell surface. Exp Cell Res 1999; 252: 352–362
   PubMedGoogle Scholar
• Baek SS, Kim KS, Nixon SB, Wilson LL, Eling JE. Cyclooxygenase inhibitors regulate the expression of a TGF beta superfamily member that has proapoptotic and antitumorogenic activities. Mol Pharmacol 2001; 59: 901–908
   PubMed Web of Science ®Google Scholar